Newborn Screening for SMA: Why DMD Deserves Equal Attention 2026

Newborn screening for spinal muscular atrophy (SMA) is a landmark victory for families and campaigners, marking a pivotal moment in pediatric healthcare. Starting in 2027, every newborn in England will be screened for SMA, allowing early diagnosis and access to life-changing treatments. Yet this breakthrough raises a critical question: why are other serious genetic conditions, such as Duchenne muscular dystrophy (DMD), still excluded from routine newborn screening? This article explores the promise of expanded screening and the urgent need for equity across all rare diseases.

The Impact of Newborn Screening for SMA

Spinal muscular atrophy is a devastating genetic disorder that causes progressive muscle weakness and often leads to early death. With newborn screening, children can receive therapies like Spinraza or Zolgensma before symptoms appear, dramatically improving outcomes. The decision to include SMA in England's screening programme is a testament to years of advocacy by families and organizations. Early diagnosis not only saves lives but also gives families clarity and the ability to plan for their child's future.

Why Duchenne Muscular Dystrophy Remains Excluded

Despite similar benefits, Duchenne muscular dystrophy (DMD) is still not part of routine newborn screening in most countries. About 100 boys are born with DMD each year in the UK. The condition causes progressive muscle degeneration, yet diagnosis often comes after years of uncertainty, multiple GP visits, and delayed referrals. Dr. Janet Hoskin, whose research focuses on families affected by DMD, notes that many parents only discover the condition after having additional children who are also affected. Early diagnosis for DMD could provide access to emerging treatments such as Givinostat, which offers hope for slowing disease progression.

Comparison of SMA and DMD Screening Status

Key Takeaways for Families and Advocates

• Newborn screening is not only about treatment access—it enables families to plan, secure specialist care, and avoid years of diagnostic delays.
• DMD affects approximately 100 boys each year in the UK, yet many experience a long, exhausting journey to diagnosis.
• Emerging therapies like Givinostat are beginning to show promise, but early diagnosis is essential for maximizing their benefit.
• Campaigners who successfully pushed for SMA screening have set a precedent—similar advocacy is needed for DMD and other rare genetic conditions.
• Every child deserves the best possible start in life, and every family deserves timely diagnosis and meaningful support.

FAQ

The success of SMA screening should be a catalyst for change. Families affected by DMD and other rare genetic conditions deserve the same opportunity for early detection. As Dr. Janet Hoskin writes, "Every child deserves the best possible start in life, and every family deserves timely diagnosis, meaningful support and the opportunity to thrive." It is time to broaden newborn screening programmes and ensure no child is left behind.